Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998
Olanzapine Can Worsen Parkinsonism
Neurol 50:1183-1184, Jimenez-Jimenez,F.J.,et al, 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Random, Placebo-Contr Study of Tolcapone in Pts with Fluctuating Parkinson Dis Trtd With Levodopa-Carbidopa
Arch Neurol 55:1089-1095, Adler,C.H.,et al, 1998
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
Clinical Usefulness of Magnetic Resonance Imaging in Multiple System Atrophy
JNNP 65:65-71, Schrag,A.,et al, 1998
Double-Blind Evaluation of Subthalamic Nucleus Deep Brain Stimulation in Advanced Parkinson's Disease
Neurol 51:850-855, Kumar,R.,et al, 1998
Effect of Selegiline on Mortality in Patients with Parkinson's Disease
Neurol 51:825-830, Olanow,C.W.,et al, 1998
Motor, Cognitive, and Behavioral Performance Following Unilateral Ventroposterior Pallidotomy for Parkinson Disease
Arch Neurol 55:1201-1208, Masterman,D.,et al, 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Ropinirole for the Treatment of Early Parkinson Disease
Arch Neurol 55:1211-1216, Sethi,K.D.,et al, 1998
Natural History & Survival of 14 Pts with Corticobasal Degeneration Confirmed as Postmortem Exam
JNNP 64:184-189, Wenning,G.K.,et al, 1998
Subcutaneous Apomorphine in Parkinson's Disease
Effective Yet Underused, BMJ 316:6411998., , 1998
Morality in DATATOP:A Multicenter Trial in Early Parkinson's Disease
Parkinson Study Group, Ann Neurol 43:318-3251998., , 1998
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Visual Fields in Patients with Posterior GPi Pallidotomy
Neurol 50:258-265, Biousse,V.,et al, 1998
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Long-Term Follow-Up of Levodopa Responsiveness in Generalized Dystonia
Arch Neurol 55:1320-1323, Dewey,R.B.,et al, 1998
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease
NEJM 337:1036-1042, Lang,A.E.,et al, 1997
Chemosensory Event-Related Potentials in Response to Trigeminal & Olfactory Stim in Idio Parkinson's Dis
Neurol 49:1424-1431, Barz,S.,et al, 1997
Olfactory Dysfunction in Familial Parkinsonism
Neurol 49:1262-1267, Markopoulou,K.,et al, 1997
Smoking and Parkinson's Disease, An Age-Dependent Risk Effect
Neurol 49:1267-1272, Tzourio,C.,et al, 1997
Pallidal Stimulation for Parkinson's Disease, Two Targets
Neurol 49:1564-1569, Bejjani,B.,et al, 1997
Frontotemporal Degeneration, Pick Disease, and Corticobasal Degeneration
Arch Neurol 54:1425-1427, 14291997., Neary,D., 1997
Frontotemporal Dementia, Pick Disease, and Corticobasal Degeneration
Arch Neurol 54:1427-1429, Kertesz,A., 1997
Clozapine in Parkinson's Disase Tremor, Effets of Acute and Chronic Administration
Neurol 49:1587-1590, Bonuccelli,U.,et al, 1997
Occupational Exposures to Metals as Risk Factors for Parkinson's Disease
Neurol 48:650-658, Gorell,J.M.,et al, 1997
Gabapentin for Parkinsonism:A Double-Blind Placebo-Controlled, Crossover Trial
Am J med 102:60-66, Olson,W.L.,et al, 1997
A Gene for Parkinson Disease
Arch Neurol 54:1156-1157, Chase,T.N., 1997
Dietary Antioxidants and Parkinson Disease
Arch Neurol 54:762-765, deRijk,M.C.,et al, 1997
What is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy
Arch Neurol 54:937-944, Litvan,I.,et al, 1997
Olfactory Dysfunction in Parkinson's Disease
JNNP 62:436-446, Hawkes,C.H.,et al, 1997
Neurological Signs and Frontal White Matter Lesions in Vascular Parkinsonism
Stroke 28:965-969, Yamanouchi,H.&Nagura,H., 1997
Distinction of Idiopathic Parkinson's Dis from Multi-Syst Atrophy by Stim of Growth-Hormone Release w Clonidine
Lancet 349:1877-1881, Kimber,J.R.,et al, 1997
Posteroventral Medial Pallidotomy in Levodopa-Unresponsive Parkinsonism
Arch Neurol 54:1026-1029, Krauss,J.K.,et al, 1997
Stereotactic Pallidotomy for Parkinson's Disease:A Long-Term Follow-up of Unilateral Pallidotomy
Neurol 48:1273-1277, Fazzini,E.,et al, 1997
Posteroventral Pallidotomy in a Patient with Parkinsonism Caused by Hypoxic Encephalopathy
Neurol 49:707-710, Goto,S.,et al, 1997
Safety and Efficacy of Pramipexole in Early Parkinson Disease
Parkinson Study Group, JAMA 278:125-1301997., , 1997
Clinical Evaluation of Pramipexole in Advanced Parkinson's Disease
Neurol 49:162-168, Lieberman,A.,et al, 1997
Efficacy of Pramipexole, A Novel Dopamine Agonist, As Monotherapy in Mild to Moderate Parkinson's Disease
Neurol 49:724-728, Shannon,K.M.,et al, 1997
Pharmacologic Profile of Ropinirole:A Nonergoline Dopamine Agonist
Neurol 49:558-562, Tulloch,I.F., 1997
Ropinirole for the Treatment of Early Parkinson's Disease
Neurol 49:393-399, Adler,C.H.,et al, 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Severe but Transient Parkinsonism after Tetanus Vaccination
JNNP 63:258, Reijneveld,J.C.,et al, 1997
Tolcapone in Stable Parkinson's Disease:Efficacy and Safety of Long-Term Treatment
Neurol 49:665-671, Waters,C.H.,et al, 1997
Serotonin Syndrome and the Combined Use of Deprenyl and An Antidepressant in Parkinson's Disease
Neurol 48:1070-1077, Richard,I.H.,et al, 1997